8-K: Pulmonx Reports 15% Revenue Growth in Third Quarter 2024, Driven by Zephyr Valve Adoption

Pulmonx Corporation announced a 15% year-over-year increase in worldwide revenue for the third quarter of 2024, reaching $20.4 million, driven by strong adoption of its Zephyr Valve treatment.

Summary

• Pulmonx reported a total worldwide revenue of $20.4 million for the third quarter of 2024, a 15% increase compared to $17.7 million in the same period of 2023.
• U.S. revenue reached $13.8 million, showing a 17% increase year-over-year, while international revenue grew by 12% to $6.6 million.
• The company's gross profit was $15.0 million, with a consistent gross margin of 74% compared to the third quarter of 2023.
• Operating expenses increased by 3% to $29.2 million, primarily due to increased commercial investments.
• Pulmonx experienced a net loss of $14.1 million, or $0.36 per share, which is an improvement from a net loss of $14.9 million, or $0.39 per share, in the third quarter of 2023.
• Adjusted EBITDA loss was $8.1 million, compared to $9.0 million for the same period last year.
• The company's cash, cash equivalents, and marketable securities totaled $107.8 million as of September 30, 2024.
• Pulmonx maintains its full-year 2024 revenue guidance of $81 million to $84 million and expects a gross margin of approximately 74%.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and consistent gross margins, but the ongoing net loss and increased operating expenses temper the overall sentiment. The clinical data and expansion efforts are encouraging, but the company still needs to address profitability concerns.

Positives

• Pulmonx achieved a significant 15% increase in worldwide revenue, indicating strong market demand.
• The 17% growth in U.S. revenue demonstrates successful commercial execution in the domestic market.
• The company maintained a consistent gross margin of 74%, showing efficient cost management.
• The addition of 15 new Zephyr Valve treatment centers in the U.S. expands patient access.
• Clinical trial data continues to support the effectiveness and durability of the Zephyr Valve treatment.
• The company's net loss improved compared to the same period last year, indicating progress towards profitability.
• Adjusted EBITDA loss decreased, suggesting improved operational efficiency.

Negatives

• The company experienced a net loss of $14.1 million for the quarter, indicating ongoing challenges with profitability.
• Operating expenses increased by 3%, primarily due to commercial investments, which may impact short-term profitability.
• The company's adjusted EBITDA loss was $8.1 million, highlighting the need for further cost management.

Risks

• The company's ability to achieve profitability is dependent on continued revenue growth and cost management.
• Increased operating expenses, particularly in commercial investments, could impact short-term financial performance.
• The company's future performance is subject to risks and uncertainties detailed in their SEC filings.

Future Outlook

Pulmonx expects full-year 2024 revenue to be in the range of $81 million to $84 million and gross margin to be approximately 74%. Total operating expenses for the full year 2024 are expected to fall within the range of $122 million to $124 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Management Comments

• Steve Williamson, President and CEO, stated he is pleased with the team's execution across commercial and clinical initiatives.
• Management remains confident in the strong underlying demand for Zephyr Valves.
• Management believes efforts to automate patient workflow, drive awareness, and expand the total addressable market will enable sustained commercial growth.

Industry Context

This announcement reflects the ongoing growth in the minimally invasive treatment market for lung diseases, with Pulmonx positioned as a key player in the COPD space. The company's focus on expanding treatment centers and driving awareness aligns with industry trends towards improving patient access to advanced medical technologies.

Comparison to Industry Standards

• Pulmonx's 15% revenue growth is a positive sign in the medical device industry, where growth rates can vary significantly depending on the specific market and product.
• Companies like Medtronic and Boston Scientific, which also operate in the medical device space, often report growth rates in the single to low double-digit percentages, making Pulmonx's growth rate competitive.
• The 74% gross margin is relatively high, indicating a strong pricing power and efficient cost management compared to other medical device companies.
• The continued expansion of treatment centers and positive clinical data are crucial for maintaining a competitive edge against other companies offering similar treatments.

Stakeholder Impact

• Shareholders will likely view the revenue growth and maintained gross margin positively, but the net loss may raise concerns.
• Employees may be encouraged by the company's growth and expansion efforts.
• Customers (hospitals and physicians) will benefit from the increased availability of the Zephyr Valve treatment.
• Patients will benefit from the continued positive clinical data and increased access to treatment.

Next Steps

• Pulmonx will host a conference call on October 30, 2024, to discuss the third quarter financial results.
• The company will continue to focus on commercial execution, expanding treatment centers, and driving awareness of the Zephyr Valve.

Key Dates

Keywords

Pulmonx, Zephyr Valve, COPD, Revenue, Gross Margin, EBITDA, Lung Disease, Financial Results, Medical Devices, Healthcare